Relief for Helixmith’s management as voting at recent shareholders' meeting failed to remove top executives, including the South Korean biotech’s founder and CEO, following recent setbacks. But the future of the board may now depend largely on the success of the ongoing clinical trials for lead assets and stock price recovery.

All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.

No evidence has been found linking the viral vector in bluebird’s gene therapy for β-thalassemia to blood cancer, the European Medicines Agency says.

Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.